Drug Trial News RSS Feed - Drug Trial News

New study to examine effectiveness of orally administered drug in treating stuttering

New study to examine effectiveness of orally administered drug in treating stuttering

Stuttering, an interruption in the flow of speech, affects about three million Americans. It begins most often in childhood, affecting four men for every woman. A precise cause of this complex communicative disorder is not known. [More]
New partnership between BetterYou and University of Sheffield paves way for vitamin D research

New partnership between BetterYou and University of Sheffield paves way for vitamin D research

A new collaboration between health pioneers BetterYou and scientists from the University of Sheffield, is paving the way for a three-year clinical trial looking at the effect of vitamin D supplementation on the quality of life of people with Irritable Bowel Syndrome (IBS). [More]
Clinical trial to examine effectiveness of diabetes drug to slow or stop progression of Parkinson's

Clinical trial to examine effectiveness of diabetes drug to slow or stop progression of Parkinson's

Type II diabetes and Parkinson's disease may not appear to have much in common but a look below the surface reveals important molecular similarities that provide a potential target for fighting Parkinson's. [More]
Changing dosing regimen could improve efficacy of malaria vaccine candidate, study shows

Changing dosing regimen could improve efficacy of malaria vaccine candidate, study shows

Researchers at the Walter Reed Army Institute of Research and collaborators recently published results of a phase II study which demonstrated that by changing the dosing regimen, the efficacy of malaria vaccine candidate, RTS,S/AS01, was improved to approximately 87%, compared with 63% using the current standard regimen. [More]
Monoclonal antibody removes brain amyloid plaques in patients with Alzheimer's disease

Monoclonal antibody removes brain amyloid plaques in patients with Alzheimer's disease

Scientists at Neurimmune today described results from the Phase 1b PRIME clinical trial of the monoclonal antibody aducanumab. [More]
HIJ-PROPER trial: Intensive cholesterol-lowering regimen in ACS patients shows no better outcomes

HIJ-PROPER trial: Intensive cholesterol-lowering regimen in ACS patients shows no better outcomes

Survival and other cardiovascular outcomes were not significantly reduced with intensive treatment using a second-line cholesterol-lowering medication on top of a standard statin, compared to statin treatment alone in patients with acute coronary syndrome (ACS) and dyslipidemia, investigators reported here. [More]
Leading Chikungunya vaccine in clinical trial phase 2

Leading Chikungunya vaccine in clinical trial phase 2

With the first patient vaccinated, a Phase 2 clinical trial of a promising prophylactic vaccine candidate against Chikungunya fever has now commenced. The product is the most advanced Chikungunya vaccine candidate globally and is developed by the Austrian biotech company Themis Bioscience GmbH. [More]
NEJM publishes MINDACT trial results

NEJM publishes MINDACT trial results

Agendia, Inc., a world leader in personalized medicine and molecular cancer diagnostics, announces the peer-reviewed publication of the primary outcome results of the Microarray In Node-negative and 1 to 3 positive lymph node Disease may Avoid ChemoTherapy (MINDACT) clinical trial in the prestigious New England Journal of Medicine (NEJM). (i, iii, iv) The publication demonstrates that 46% of breast cancer patients considered for chemotherapy, whose tumors are classified MammaPrint Low Risk, have excellent survival without chemotherapy, and can thus be candidates to avoid this toxic therapy. [More]
BirchBioMed announces successful completion of Phase I trial for topical treatment to prevent scarring

BirchBioMed announces successful completion of Phase I trial for topical treatment to prevent scarring

BirchBioMed Inc. announced today that a unique and ground-breaking topical treatment developed by University of British Columbia researchers to prevent scarring has completed a Health Canada approved Phase I trial. [More]
Fiocruz to start phase II clinical trials of novel vaccine for schistosomiasis

Fiocruz to start phase II clinical trials of novel vaccine for schistosomiasis

The Oswaldo Cruz Foundation at Rio de Janeiro, Brazil, will start the phase II clinical trials of a vaccine for schistosomiasis, called 'Sm14 Vaccine'. [More]
Anesthetic administered with nasal spray effective in preventing pain during dental treatment

Anesthetic administered with nasal spray effective in preventing pain during dental treatment

A fear of pain causes many people with dental phobias to avoid or delay needed treatment. In some cases, the injection of a numbing agent can be the most painful part of the visit. [More]
SSRI treatment improves cognitive and social functioning in young children with fragile X

SSRI treatment improves cognitive and social functioning in young children with fragile X

Treatment with sertraline may provide nominal but important improvements in cognition and social participation in very young children with fragile X syndrome, the most common genetic cause of intellectual disability and the leading single-gene cause of autism, a study by researchers with the UC Davis MIND Institute has found. [More]
Three like-minded nonprofits collaborate to launch immunotherapy clinical trial for pediatric brain tumors

Three like-minded nonprofits collaborate to launch immunotherapy clinical trial for pediatric brain tumors

A Kids' Brain Tumor Cure Foundation, Solving Kids' Cancer and the Ty Louis Campbell Foundation announce their joint financial support of a Phase 1 clinical trial to test the safety and efficacy of combination checkpoint inhibitors in the treatment of children with brain tumors. [More]
New clinical trial to examine safety of checkpoint inhibitor in pediatric cancer patients

New clinical trial to examine safety of checkpoint inhibitor in pediatric cancer patients

In an innovative, first-in-pediatrics study, available only at Children's Hospital Los Angeles, researchers will be enrolling children between 1 and 18 years of age who have certain types of relapsed or treatment-resistant cancer. [More]
BCL-2 inhibitor shows promise in AML patients

BCL-2 inhibitor shows promise in AML patients

Patients whose acute myelogenous leukemia (AML) had relapsed or was resistant to chemotherapy and those who were deemed unable to tolerate chemotherapy experienced responses to the selective BCL-2 inhibitor venetoclax (Venclexta), with complete remissions in some, according to phase II clinical trial data. [More]
CTCA at Western begins clinical trial for novel antibody to treat patients with advanced tumors

CTCA at Western begins clinical trial for novel antibody to treat patients with advanced tumors

Cancer Treatment Centers of America at Western Regional Medical Center has dosed its first three patients as part of the launch of a Phase I clinical trial using a novel antibody to treat patients with advanced solid tumors. [More]
Study demonstrates significant reduction in severity of exercise-induced asthma following B-GOS consumption

Study demonstrates significant reduction in severity of exercise-induced asthma following B-GOS consumption

Clasado Biosciences Limited, the producers and suppliers of Bimuno(R) (B-GOS), a unique patented trans-galactooligosaccharide complex, today announces the publication of results for the latest clinical study using B-GOS. [More]
NIH launches clinical trial of experimental vaccine candidate for preventing Zika virus infection

NIH launches clinical trial of experimental vaccine candidate for preventing Zika virus infection

The National Institute of Allergy and Infectious Diseases, part of the National Institutes of Health, has launched a clinical trial of a vaccine candidate intended to prevent Zika virus infection. [More]
Combination therapy shows no better benefits than placebo for patients with knee osteoarthritis

Combination therapy shows no better benefits than placebo for patients with knee osteoarthritis

Chondroitin sulfate (CS) plus glucosamine sulfate (GS) was no better than placebo for reducing pain and function impairment in a multicenter, randomized, double-blinded, placebo-controlled study of 164 patients with knee osteoarthritis. [More]
NIAID begins early-stage trial of experimental vaccine for preventing yellow fever virus

NIAID begins early-stage trial of experimental vaccine for preventing yellow fever virus

The National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health, has begun an early-stage clinical trial of an investigational vaccine designed to protect against yellow fever virus. [More]
Advertisement
Advertisement